3/7/2007 Columbus, OH Glen Forbes The lantern (media.www.thelantern.com) Dale Stokes owns a 230-acre farm in Wilmington, Ohio, but he is also in the business of saving lives. Stokes is the main berry provider for cancer researchers at Ohio State who are attempting to prove that consumption of certain berries, particularly blackberries, black raspberries and strawberries, can stop the spread of colon, esophageal and oral cancer. "I would estimate that I've given about 15,000 pounds of berries over 20 years to this research," Stokes said. "To ensure consistency, I grow all of the black raspberries at Ohio State in the same patch of roughly three acres." Several groups of researchers based at the OSU Medical Center are studying the effects of berry consumption. Black raspberries and blackberries have proven to be particularly effective in reducing the size and spread of tumors in rats with oral and esophageal cancer, according to Dr. Gary Stoner. He has led the research regarding the positive effects of antioxidants in berries for more than 20 years. "I first heard about Dr. Stoner's work in 1987 when he was with the Ohio College of Medicine in Toledo," Stokes said. "I heard what he was trying to do and I approached him and told him I was the largest individual grower of black raspberries east of the Mississippi." In the early 1980s, Stoner and his research group began working with a compound that featured ellagic acid - a plant nutrient that is plentiful in several types of berries. [...]

3/7/2007 Cleveland, OH press release FDA Recall List (www.fda.gov/opacom) Gebauer Company, a 107-year-old medical device manufacturer and marketer, today announced a nationwide, voluntary firm initiated recall of certain lots of its Salivart Oral Moisturizer, product number 0386-0009-75. These lots may contain some units that do not meet the Company's internal specification for aerobic microorganisms and mold. The problem was discovered during routine stability testing. The problem is not uniform throughout the lots. Use of the affected units of these lots of Salivart Oral Moisturizer may cause temporary and reversible health problems such as nausea, vomiting, and diarrhea. Lot numbers and expiration dates are located on the bottom of the product can. The recalled product lots are: Lot Number Expiration Date Initial Ship Date 06AA001 06-08 09-11-06 06AA002 06-08 10-05-06 06AA003 06-08 10-26-06 06AA004 07-08 11-16-06 06AA005 07-08 12-14-06 06AA006 10-08 01-10-07 Customers who believe they are in possession of the recalled product should stop using the product and dispose of it immediately in their regular trash. "We are committed to the quality of our products and we are taking all necessary measures to remedy this production issue," said John Giltinan, President of Gebauer Company. "Salivart Oral Moisturizer has been used safely since 1990 and is supported by our history of meeting high safety and efficacy standards." Should customers require additional information, they are to contact Gebauer Company Customer Service at (800) 321-9348.

3/7/2007 Stockholm, Sweden A Roosaar et al. J Oral Pathol Med, February 1, 2007; 36(2): 78-82 Aim: To assess the natural course of screening-detected oral leukoplakia (OL) among non-consulting individuals. Methods: A cohort of 555 individuals with OL, confirmed in 1973-1974 during a population-based survey, were followed through January 2002 via record linkages with nationwide and essentially complete registers. A sample of 104 drawn from the 297 surviving cohort members who still were living in the area in 1993-1995 was invited to a re-examination. Sixty-seven of them attended. Results: At the time of re-examination OL had disappeared in 29 (43%) individuals. There was a statistically significant association between cessation of/no smoking habits in 1993-1995 and the disappearance of OL. Never/previous daily smokers were thus over-represented among individuals whose OL had disappeared compared to those with persisting OL [n = 23 (82%) vs. n = 18 (47%), P < 0.01]. Eighteen (78%) of the twenty three non-smokers with disappearing OL had quit after the initial examination. One man and two women developed oral cancer during follow-up while 0.7 and 0.07, respectively, were expected. Conclusion: Smoking cessation was associated with an increased disappearance of OL. Hence, at least one-fourth had lesions that could be classified as tobacco-related. Small observed and expected numbers prohibited firm conclusions about a possible excess risk of developing oral cancer. Authors: A Roosaar, L Yin, AL Johansson, G Sandborgh-Englund, O Nyren, and T Axell Authors' affiliation: Institute of Odontology, Karolinska Institutet, Stockholm, Sweden

3/7/2007 Vancouver, British Columbia, Canada Miriam P Rosin Ann. N.Y. Acad. Sci., March 1, 2007 The genomic era has fueled a rapid emergence of new information at the molecular level with a great potential for developing innovative approaches to detection, risk assessment and management of oral cancers and premalignant disease. As yet, however, little research has been done on complementary approaches that would use different technology in conjunction with molecular approaches to create a rapid and cost-effective strategy for patient assessment and management. In our ongoing 8-year longitudinal study, a set of innovative technologies is being validated alone and in combination to best correlate with patient outcome. The plan is to use these devices in a step-by-step sequence to guide key clinicopathological decisions on patient risk and treatment. The devices include a hand-held visualization device which makes use of tissue autofluorescence to detect and delineate abnormal lesions and fields requiring follow-up, to be used in conjunction with optical contrast agents such as toluidine blue. In addition, two semi-automated high-resolution computer microscopy systems will be used to quantitate the protein expression phenotype of cell nuclei in tissue sections and exfoliated cell brushings. Previously identified risk-associated molecular changes are being used to validate these systems as well as to establish their place in a population-based triage program that will filter out high-risk cases in the community and funnel them to dysplasia clinics where higher-cost molecular tools will guide intervention. A critical development for the translation of this technology into community settings is [...]

3/6/2007 New Rochelle, NY press release Genetic Engineering News (www.genengnews.com) Cytogen Corporation today announced the launch of Caphosol Relieves Oral Mucositis, an educational support program for patients and caregivers. The announcement comes as Cytogen establishes an expanded market presence for Caphosol, an advanced electrolyte solution indicated in the U.S. as an adjunct to standard oral care in treating oral mucositis (OM) caused by radiation or high dose chemotherapy. Caphosol, a prescription medical device, is also indicated for dryness of the mouth or throat (hyposalivation, xerostomia), regardless of the cause or whether the conditions are temporary or permanent.(1) Caphosol is available through U.S. wholesalers nationwide. CARE OM As part of its commitment to advancing the treatment and care of cancer patients, Cytogen is proud to announce the launch of CARE OM - a web-based education and support center for patients and caregivers seeking to learn more about OM and Caphosol . In addition to oral mucositis educational material and support information, visitors to CARE OM, located at http://www.caphosol.com/careom, can also download an OM brochure or request a free brochure about OM by mail. "The CARE OM program is designed to help raise awareness of oral mucositis --one of the most common and debilitating complications of cancer treatment," said Michael D. Becker, president and chief executive officer of Cytogen Corporation. "As we make Caphosol more widely available in the U.S., our goal is to improve the quality of cancer patients' lives through the effective management of oral mucositis." Oral complications including mucositis [...]

3/6/2007 Pittsburgh, PA Allison M. Heinrichs Pittsburgh Tribune-Review (www.pittsburghlive.com) Lugging a suitcase filled with 600 DNA samples from people with oral deformities sparked an idea for Dr. Alexandre Vieira that simmered for seven years. That idea has since grown into the world's first dental DNA registry -- and all people have to do to help is spit into a cup. "Anything that you can imagine related to dentistry can be examined in this way," said Vieira, a dentist and assistant professor in Pitt's Center for Craniofacial and Dental Genetics. The registry allows qualified researchers access to a person's dental records -- anonymously -- along with a sample of that person's DNA, collected from saliva. Potential research projects include everything from determining whether cavities have a genetic link, to testing whether a particular couple is prone to having a baby with an oral defect, such as a cleft palate. By having a pre-existing DNA registry, Vieira expects to save Pitt and other dental research centers almost $125,000 per genetics study because researchers won't have to collect new samples. The project began in September in one of the dental school's 20-chair Oakland clinics. Patients who indicate they are willing to participate in the study sign a waiver and spit into a special cup. When Vieira started the study, he expected about 30 percent of the patients to agree. So far, 85 percent of patients have done so, and Vieira has collected almost 250 samples. He's hoping to collect 1,000 each year, with [...]

3/5/2007 Barcelona, Spain Bruce Sylvester Doctor's Guide (www.docguide.com) Addition of fluorodeoxyglucose (FDG)-positron emission tomography (PET) to computed tomography (CT) alters gross tumour volume readings for a significant number of patients with head and neck cancer, which can affect treatment decisions. The findings were presented in an oral session here on February 23rd at the International Meeting on Innovative Approaches in Head and Neck Oncology, sponsored by the European Head and Neck Society and the European Society for Therapeutic Radiology and Oncology (EHNS-ESTRO). "Our findings suggest that, for tumours of the head and neck which are to be treated with primary chemoradiography, combined FDG-PET-CT will provide optimal treatment guidance compared to CT alone," said presenter and lead investigator Christian Terhaard, MD, PhD, associate professor of radiology, University of Utrecht, Utrecht, The Netherlands. The investigators compared the CT and FDG-PET-CT images of 109 patients treated at the University Medical Centre in Utrecht between 2003 and 2006 for primary squamous cell carcinoma of the head and neck (95%) or for recurrent disease (5%). The scans were taken using the same mould for each patient. A radiation oncologist and a nuclear medicine physician matched and analysed the images and evaluated them for differences in the gross tumour volume and change of treatment preference. Tumours were located in the pharynx (76%), larynx (11%) and oral cavity (13%). Advanced T-stage (tumour size and extent of primary tumour) of T3-4 appeared in 46% of the subjects; neck nodes were positive in 61%. The researchers reported that the [...]

3/4/2007 Barcelona, Spain Bruce Sylvester Doctor's Guide (www.docguide.com) Free-flap reconstruction following head and neck cancer surgery produces acceptable quality-of-life outcomes, researchers reported here at the International Meeting on Innovative Approaches in Head and Neck Oncology, sponsored by the European Head and Neck Society and the European Society for Therapeutic Radiology and Oncology (EHNS-ESTRO). "While the outcomes were acceptable, clearly new reconstructive procedures are also needed," said lead investigator and presenter Gilles Poissonnet, MD, surgeon, Centre Antoine Lacassagne, Nice, France, in an oral session here on February 24th. Dr. Poissonnet and colleagues enrolled 65 consecutive patients who underwent head and neck reconstructive surgery with free flaps between 2004 and 2005. Before surgery and both 6 months and 12 months after surgery, subjects completed 2 questionnaires -- the European Organisation for Research and Treatment of Cancer quality-of-life questionnaires (QLQ-C30 and QLQ-H&N35). The investigators looked at predictive factors of poor quality of life including age, comorbidities, preoperative radiotherapy, tumour stage, type of surgery, and type of defect repaired. Results showed that global quality of life decreased slightly at 6 months after surgery and remained fairly constant at 6 and 12 months. Physical functioning, role functioning and social functioning declined significantly at the 1-year evaluation (P < .05), and emotional and cognitive functioning remained stable. Pain decreased significantly after treatment (P < .05). Eating, speaking, and sensorial problems increased significantly, with a slight deterioration between 6 and 12 months. The authors concluded, "Free flap reconstruction of head and neck defects allows good functional results [...]

3/4/2007 Houston, TX Martha V. Mar et al. Journal of Nuclear Medicine Technology Volume 35, Number 1, 2007 10-16 In patients with head and neck tumors, preoperative lymphoscintigraphy can be used to map lymphatic drainage patterns and identify sentinel lymph nodes. However, it is very difficult to determine the exact locations of head and neck sentinel nodes on preoperative lymphoscintigraphy without the use of anatomic landmarks. Lymph nodes in the head and neck are grouped into 7 regions, or levels, on the basis of anatomic landmarks. In patients undergoing standard lymphoscintigraphy, obtaining lateral marker images that show important anatomic landmarks can help with the localization of sentinel nodes. However, technical problems often render marker images of little or no use. Hybrid SPECT/CT (single photon emission controlled tomography) lymphoscintigraphic imaging facilitates the localization of sentinel nodes by reliably showing the relationships between sentinel nodes and important anatomic structures. After reading this article, the reader should understand the lymph node level classification system for head and neck melanomas, be able to describe the technique used for the imaging of sentinel nodes in the head and neck region, and be able to demonstrate how SPECT/CT lymphoscintigraphic imaging can enable precise sentinel node localization and thus help to ensure minimal dissection. Authors: Martha V. Mar1, Scott A. Miller2, E. Edmund Kim1 and Homer A. Macapinlac1 Authors' affiliations: 1 Department of Nuclear Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, Texas; and 2 Department of Imaging Physics, The University of Texas M.D. Anderson [...]

3/2/2007 Rancho Mirage, CA Jennifer R. Grandis, MD Medscape Today (www.medscape.com) Introduction: The Multidisciplinary Head and Neck Cancer Symposium, cosponsored by the American Society for Therapeutic Radiology and Oncology and the American Society of Clinical Oncology, was held in Rancho Mirage, California, from January 18-20, 2007. Several presentations focused on advances in the medical management of patients with head and neck cancer (HNC). Despite increasing awareness of the cancer-inducing effects of tobacco, the incidence of HNC has not decreased worldwide. Efforts to prevent these tumors through pharmacologic intervention have largely failed, and early detection strategies have not been successful. Thus, most patients with HNC present with advanced (stages III and IV) disease. Oral cavity tumors are treated primarily with surgical resection due to the toxicity of radiation in this region (eg, osteoradionecrosis). Advanced tumors of the pharynx and larynx are generally treated with combined modality therapy (chemoradiation [CRT]), with surgery reserved for neck dissection when the patient presents with advanced neck disease (N2 or N3) and/or has an incomplete response in the neck to CRT. The major advance in the management of HNC continues to be the integration of targeted therapeutics into treatment regimens. Inhibiting the Epidermal Growth Factor Receptor: The landmark Radiation Therapy Oncology Group trial[1] comparing the epidermal growth factor receptor (EGFR) monoclonal antibody cetuximab plus radiation vs radiation alone led to approval of this agent by the US Food and Drug Administration (FDA) in 2006 for the treatment of HNC. Cetuximab was the first drug approved for [...]